ATE343388T1 - Pde-v hemmer zur behandlung von morbus parkinson - Google Patents

Pde-v hemmer zur behandlung von morbus parkinson

Info

Publication number: ATE343388T1
Authority: AT; Austria
Prior art keywords: disease; parkinson; pde; inhibitor; treatment
Prior art date: 2000-04-19

Application number

AT01929063T

Other languages

English (en)

Inventor

H H Roylance

Original Assignee

Lilly Icos Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-04-19

Filing date

2001-04-17

Publication date

2006-11-15

2001-04-17 Application filed by Lilly Icos Llc filed Critical Lilly Icos Llc

2006-11-15 Application granted granted Critical

2006-11-15 Publication of ATE343388T1 publication Critical patent/ATE343388T1/de

Links

208000018737 Parkinson disease Diseases 0.000 title abstract 2
239000002590 phosphodiesterase V inhibitor Substances 0.000 title 1
ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 abstract 1
229940099471 Phosphodiesterase inhibitor Drugs 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 abstract 1
239000002571 phosphodiesterase inhibitor Substances 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AT01929063T 2000-04-19 2001-04-17 Pde-v hemmer zur behandlung von morbus parkinson ATE343388T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US19818000P	2000-04-19	2000-04-19

Publications (1)

Publication Number	Publication Date
ATE343388T1 true ATE343388T1 (de)	2006-11-15

Family

ID=22732318

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT01929063T ATE343388T1 (de)	2000-04-19	2001-04-17	Pde-v hemmer zur behandlung von morbus parkinson

Country Status (9)

Country	Link
US (2)	US20020006926A1 (de)
EP (1)	EP1278522B1 (de)
JP (1)	JP2004500425A (de)
CN (1)	CN1436080A (de)
AT (1)	ATE343388T1 (de)
AU (2)	AU5584901A (de)
CA (1)	CA2407031A1 (de)
DE (1)	DE60124085D1 (de)
WO (1)	WO2001078711A2 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10135815A1 (de) *	2001-07-23	2003-02-06	Bayer Ag	Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen
IL160307A0 (en)	2001-08-31	2004-07-25	Univ Rockefeller	Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain
US8338420B1 (en)	2002-12-04	2012-12-25	Mitsubishi Tanabe Pharma Corporation	Treatment of Parkinson's disease and enhancement of dopamine signal using PDE 10 inhibitor
US20050048573A1 (en) *	2003-02-03	2005-03-03	Plexxikon, Inc.	PDE5A crystal structure and uses
AU2006255028B2 (en)	2005-06-06	2012-04-19	Intra-Cellular Therapies, Inc.	Organic compounds
US20080194592A1 (en) *	2005-08-23	2008-08-14	Intra-Cellular Therapies, Inc.	Organic Compounds
JP5701485B2 (ja)	2006-02-21	2015-04-15	テバファーマシューティカルインダストリーズリミティド	多系統萎縮症の治療のためのラサギリンの使用
KR20090042227A (ko) *	2006-06-06	2009-04-29	인트라-셀룰라 써래피스, 인코퍼레이티드.	유기 화합물
TW200815045A (en) *	2006-06-29	2008-04-01	Jazz Pharmaceuticals Inc	Pharmaceutical compositions of ropinirole and methods of use thereof
US8841300B2 (en)	2006-10-02	2014-09-23	Jerry M. Held	Treatment for Parkinson's disease—combination high dose serotonergic synaptic reuptake inhibitor with phosphodiesterase inhibitor
WO2008063505A1 (en) *	2006-11-13	2008-05-29	Intra-Cellular Therapies, Inc.	Organic compounds
WO2008070095A1 (en)	2006-12-05	2008-06-12	Intra-Cellular Therapies, Inc.	Novel uses
CN101754756A (zh) *	2007-05-18	2010-06-23	维瓦斯公司	包含磷酸二酯酶-5抑制剂的新组合和它们的用途
EP2240028B1 (de) *	2007-12-06	2016-07-20	Intra-Cellular Therapies, Inc.	Pyrazolopyrimidine-4,6-dione derivate und deren Anwendung als Pharmaceutika
KR20120012831A (ko)	2007-12-06	2012-02-10	인트라-셀룰라 써래피스, 인코퍼레이티드.	유기 화합물
US8969417B2 (en)	2008-06-06	2015-03-03	Pharmatwob Ltd.	Pharmaceutical compositions for treatment of Parkinsons disease
EP2367431B1 (de)	2008-12-06	2015-08-05	Intra-Cellular Therapies, Inc.	Organische verbindungen
JP5778582B2 (ja)	2008-12-06	2015-09-16	イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−ＣｅｌｌｕｌａｒＴｈｅｒａｐｉｅｓ，Ｉｎｃ．	有機化合物
EP2367430B1 (de)	2008-12-06	2014-08-13	Intra-Cellular Therapies, Inc.	Organische verbindungen
MA32942B1 (fr)	2008-12-06	2012-01-02	Intra Cellular Therapies Inc	Composes organiques
KR20110103949A (ko) *	2008-12-06	2011-09-21	인트라-셀룰라 써래피스, 인코퍼레이티드.	유기 화합물
BRPI0922809A2 (pt)	2008-12-06	2018-05-29	Intracellular Therapies Inc	compostos orgânicos
WO2010098839A1 (en)	2009-02-25	2010-09-02	Intra-Cellular Therapies, Inc.	Pde 1 inhibitors for ophthalmic disorders
JP2012526810A (ja)	2009-05-13	2012-11-01	イントラ−セルラー・セラピーズ・インコーポレイテッド	有機化合物
JP6166534B2 (ja)	2009-08-05	2017-07-19	イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−ＣｅｌｌｕｌａｒＴｈｅｒａｐｉｅｓ，Ｉｎｃ．	新規調節タンパク質および阻害剤
WO2011153135A1 (en)	2010-05-31	2011-12-08	Intra-Cellular Therapies, Inc.	Organic compounds
WO2011153136A1 (en)	2010-05-31	2011-12-08	Intra-Cellular Therapies, Inc.	Organic compounds
TW201206937A (en)	2010-05-31	2012-02-16	Intra Cellular Therapies Inc	Organic compounds
EP2576551A4 (de)	2010-05-31	2014-04-16	Intra Cellular Therapies Inc	Organische verbindungen
JP6051210B2 (ja) *	2011-06-10	2016-12-27	イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−ＣｅｌｌｕｌａｒＴｈｅｒａｐｉｅｓ，Ｉｎｃ．	有機化合物
US20150086481A1 (en) *	2011-07-28	2015-03-26	Memorial Sloan-Kettering Cancer Center	Diagnosis and treatment of parkinson's disease
US9801882B2 (en)	2013-02-17	2017-10-31	Intra-Cellular Therapies, Inc.	Phosphodiesterase-1 inhibitors and their use in treatment of cardiovascular diseases
EP2968338B1 (de)	2013-03-15	2019-01-09	Intra-Cellular Therapies, Inc.	Pde1-inhibitoren zur verwendung bei der behandlung und/oder prävention von zns-verletzungen und pns-krankheiten, störungen oder verletzungen
KR102240326B1 (ko)	2013-03-15	2021-04-13	인트라-셀룰라 써래피스, 인코퍼레이티드.	유기 화합물
US9463186B2 (en)	2013-04-15	2016-10-11	Northwestern University	Treatment for dopaminergic disorders
JP6696904B2 (ja)	2014-01-08	2020-05-20	イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−ＣｅｌｌｕｌａｒＴｈｅｒａｐｉｅｓ，Ｉｎｃ．	製剤および医薬組成物
EP3157926B1 (de)	2014-06-20	2019-05-15	Intra-Cellular Therapies, Inc.	Organische verbindungen
US9546175B2 (en)	2014-08-07	2017-01-17	Intra-Cellular Therapies, Inc.	Organic compounds
US10285992B2 (en)	2014-08-07	2019-05-14	Intra-Cellular Therapies, Inc.	Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
US10131671B2 (en)	2014-08-07	2018-11-20	Intra-Cellular Therapies, Inc.	Organic compounds
CA2961212C (en)	2014-09-17	2024-02-06	Intra-Cellular Therapies, Inc.	Compounds and methods
CA2969594A1 (en)	2014-12-06	2016-06-09	Intra-Cellular Therapies, Inc.	Pde2 inhibiting organic compounds
HK1244427A1 (zh)	2014-12-06	2018-08-10	Intra-Cellular Therapies, Inc.	有机化合物
US10682354B2 (en)	2016-03-28	2020-06-16	Intra-Cellular Therapies, Inc.	Compositions and methods
WO2017168174A1 (en)	2016-04-02	2017-10-05	N4 Pharma Uk Limited	New pharmaceutical forms of sildenafil
JP7134168B6 (ja)	2016-09-12	2024-02-02	イントラ－セルラー・セラピーズ・インコーポレイテッド	新規使用
US20200009213A1 (en) *	2017-03-02	2020-01-09	Universiteit Van Amsterdam	Specific Increase of Dopamine Synthesis THrough Targeting of the Guanylate Cyclase 2C Receptor in the Treatment of Parkinson's Disease
JP7401442B2 (ja)	2018-01-31	2023-12-19	イントラ－セルラー・セラピーズ・インコーポレイテッド	新規使用
FI3846788T3 (fi) *	2018-09-05	2025-12-17	Univ Amsterdam	Pde11-estäjiä parkinsonin taudin hoitoon
EP4413980A3 (de)	2019-09-03	2024-10-30	Intra-Cellular Therapies, Inc.	Neue verbindungen
US12364695B2 (en)	2020-06-02	2025-07-22	Intra-Cellular Therapies, Inc.	Methods of treating inflammatory disease

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4147789A (en) *	1974-03-14	1979-04-03	Sandoz Ltd.	6-Methyl-8-thiomethyl-ergolene derivatives
ATE199569T1 (de)	1993-05-27	2001-03-15	Univ Washington	Cyclisch gmp bindende cyclisch gmp spezifische phosphodiesterase materialien und verfahren.
GB9401090D0 (en)	1994-01-21	1994-03-16	Glaxo Lab Sa	Chemical compounds
GB9514465D0 (en)	1995-07-14	1995-09-13	Glaxo Lab Sa	Chemical compounds
GB9514473D0 (en)	1995-07-14	1995-09-13	Glaxo Lab Sa	Chemical compounds
WO1997024334A1 (en) *	1995-12-28	1997-07-10	Fujisawa Pharmaceutical Co., Ltd.	Benzimidazole derivatives
BR9709230A (pt)	1996-05-10	1999-08-10	Icos Corp	Composto
WO1998053819A1 (en)	1997-05-29	1998-12-03	Mochida Pharmaceutical Co., Ltd.	Therapeutic agent for erection failure
JP2002509553A (ja)	1997-10-27	2002-03-26	藤沢薬品工業株式会社	ｃＧＭＰ−ＰＤＥ阻害剤としての三環式化合物
CA2395558C (en)	1997-11-12	2007-07-17	Bayer Aktiengesellschaft	Intermediates for 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
WO1999026946A1 (en)	1997-11-26	1999-06-03	Mochida Pharmaceutical Co., Ltd.	PYRIDOCARBAZOLE DERIVATIVES WITH cGMP-PDE INHIBITORY ACTIVITY
DE19752952A1 (de)	1997-11-28	1999-06-02	Merck Patent Gmbh	Thienopyrimidine
ZA9810766B (en)	1997-11-28	1999-05-25	Mochida Pharm Co Ltd	Novel compounds having cgmp-pde inhibitory activity
AU752072B2 (en) *	1997-12-12	2002-09-05	Osi Pharmaceuticals, Inc.	N-benzyl-3-indenylacetamides derivatives for treating neoplasia
AU755361B2 (en)	1998-02-19	2002-12-12	Eisai R&D Management Co., Ltd.	Phthalazine derivatives and remedies for erectile dysfunction
DE69906059D1 (de)	1998-04-20	2003-04-24	Fujisawa Pharmaceutical Co	Anthranilsäurederivate als inhibitoren der c-gmp-phosphodiesterase
RS50011B (sr)	1998-04-20	2008-09-29	Pfizer Inc.,	Derivati piridin-3-karboksilne kiseline i njihova upotreba kao intermedijera
WO2001032170A1 (en) *	1999-09-13	2001-05-10	Swope David M	Composition and method for decreasing neurologic symptomatology

2001
- 2001-04-17 US US09/836,744 patent/US20020006926A1/en not_active Abandoned
- 2001-04-17 AT AT01929063T patent/ATE343388T1/de not_active IP Right Cessation
- 2001-04-17 CA CA002407031A patent/CA2407031A1/en not_active Abandoned
- 2001-04-17 EP EP01929063A patent/EP1278522B1/de not_active Expired - Lifetime
- 2001-04-17 JP JP2001576012A patent/JP2004500425A/ja not_active Withdrawn
- 2001-04-17 WO PCT/US2001/040538 patent/WO2001078711A2/en not_active Ceased
- 2001-04-17 DE DE60124085T patent/DE60124085D1/de not_active Expired - Lifetime
- 2001-04-17 AU AU5584901A patent/AU5584901A/xx active Pending
- 2001-04-17 AU AU2001255849A patent/AU2001255849B8/en not_active Ceased
- 2001-04-17 CN CN01811222A patent/CN1436080A/zh active Pending
- 2001-11-21 US US09/989,672 patent/US6492371B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
AU2001255849B2 (en)	2005-12-22
CA2407031A1 (en)	2001-10-25
EP1278522A2 (de)	2003-01-29
AU2001255849B8 (en)	2006-04-27
US20020006926A1 (en)	2002-01-17
JP2004500425A (ja)	2004-01-08
WO2001078711A2 (en)	2001-10-25
DE60124085D1 (de)	2006-12-07
AU5584901A (en)	2001-10-30
CN1436080A (zh)	2003-08-13
US20020077274A1 (en)	2002-06-20
US6492371B2 (en)	2002-12-10
EP1278522B1 (de)	2006-10-25
WO2001078711A3 (en)	2002-07-04

Legal Events

Date	Code	Title	Description
2007-04-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE60124085D1 (de)	2006-12-07	Pde-v hemmer zur behandlung von morbus parkinson
ATE389395T1 (de)	2008-04-15	Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson
EA200201247A1 (ru)	2003-10-30	Соединения для лечения болезни альцгеймера
DE60124080D1 (de)	2006-12-07	Verbindungen und verfahren zur behandlung der alzheimerschen krankheit
ATE302751T1 (de)	2005-09-15	Verbindungen zur behandlung der alzheimerischen krankheit
ATE355374T1 (de)	2006-03-15	Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
EA200600294A1 (ru)	2006-08-25	[1,8] нафтиридин-2-оны и родственные соединения для лечения шизофрении
GB0318447D0 (en)	2003-09-10	Therapeutic agents
EA200300528A1 (ru)	2003-10-30	1-арил-или 1-алкилсульфонилгетероциклилбензазолы в качестве лигандов 5-гидрокситриптамина-6
WO2002002520A8 (en)	2003-11-13	Compounds to treat alzheimer's disease
ATE254461T1 (de)	2003-12-15	Behandlung von augenschmerzen
EA200401114A3 (ru)	2005-06-30	Замещённые гидроксиэтиламины
IL162515A0 (en)	2005-11-20	Substituted diketopiperazines as oxytocin antagonists
ATE466569T1 (de)	2010-05-15	Nasale verabreichung von metoclopramid zur behandlung der gastroparese
ATE217191T1 (de)	2002-05-15	Verwendung von phanquinon zur behandlung von alzheimer's krankheit
ATE464048T1 (de)	2010-04-15	Behandlung von alzheimer-krankheit und verwandten zuständen
ATE437855T1 (de)	2009-08-15	(4,5,6,7-tetrahydro-1h-indol-7- yl)essigsäurederivate zur behandlung von alzheimer-krankheit
ATE315387T1 (de)	2006-02-15	Verwendung von substituierten 6- dimethylaminomethyl-1-phenyl- cyclohexanverbindungen zur therapie der harninkontinenz
DE60330233D1 (de)	2010-01-07	Arsentherapie zur behandlung von autoimmunerkrankungen
DE59609219D1 (de)	2002-06-20	Verwendung von 1-hydroxy-2-pyridonen zur behandlung von schwer therapierbaren schleimhauterkrankungen
DE60108775D1 (de)	2005-03-10	Methode zur behandlung von schlaganfall
DE60310975D1 (de)	2007-02-15	Verwendung von epothilone zur behandlung hyperparathyreoidismus
ATE431348T1 (de)	2009-05-15	Thiaepothilone zur behandlung von krebserkrankungen